New Factors Influencing Exagen's Story
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy XGN?
Source: Yahoo Finance
Exagen's Fair Value and Growth Outlook: Exagen's long-term fair value remains at approximately $15.43 per share, with revenue growth expectations steady at around 15.14%, driven by the expanding adoption of AVISE CTD in autoimmune diagnostics.
Analyst Ratings and Price Targets: B. Riley initiated a Buy rating with a $15 price target, while Canaccord raised its target from $11 to $15, both highlighting the potential of AVISE CTD as a leading diagnostic tool despite sector challenges.
Sector Challenges and Company Confidence: Canaccord warns of pressures in the life science tools sector due to tariffs and funding uncertainties, but Exagen maintains its revenue guidance of $65M to $70M for 2025, aiming for positive adjusted EBITDA by Q4 2025.
Dynamic Investor Narratives: Investors are encouraged to follow Exagen's evolving narrative on Simply Wall St, which connects company performance with future forecasts, helping to inform buy or sell decisions based on the latest updates and market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XGN
Wall Street analysts forecast XGN stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.250
Low
13.00
Averages
15.20
High
18.00
Current: 3.250
Low
13.00
Averages
15.20
High
18.00
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exagen Inc. Reports Record Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Exagen achieved a record $66.6 million in revenue for 2025, nearly a 20% increase over 2024, with testing volume up over 11%, indicating strong performance and sustained customer demand in its market.
- Sales Team Expansion: The sales force expanded from 40 to 45 territories, aiming to drive future revenue growth through broader market coverage and more efficient customer service, which is expected to enhance market share further.
- Product Development Plan: The company plans to launch one new product each year, with a myositis solution targeted for 2027, demonstrating Exagen's strategic commitment to expanding its market opportunities and product portfolio.
- Profitability Outlook: Exagen projects 2026 revenue guidance between $70 million and $73 million, with management confident that breakeven adjusted EBITDA can be achieved at an $80 million revenue run rate, reflecting a strong focus on future growth and investment priorities.
See More
Exagen Reports Q4 Earnings Miss Despite Revenue Growth
- Earnings Performance: Exagen's Q4 GAAP EPS of -$0.20 misses expectations by $0.01, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Growth: The company reported revenue of $16.63 million, reflecting a 21.7% year-over-year increase, surpassing market expectations by $0.06 million, suggesting improved sales performance despite the earnings miss.
- Future Outlook: Exagen anticipates full-year 2026 revenue between $70 million and $73 million, compared to the consensus of $73.84 million, indicating a cautious outlook that may influence shareholder perceptions of its long-term strategy.
- Market Reaction: Despite revenue growth, Exagen's performance lags behind peers like Avino Silver & Gold and Harmony Gold, potentially prompting investors to reassess the risk and return profile of their portfolios.
See More
Exagen Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Exagen Inc. will participate in the virtual KeyBank Capital Markets Healthcare Forum on March 17, 2026, with investor meetings and a fireside chat at 3:00 p.m. ET, aimed at enhancing the company's visibility among investors.
- Key Meeting Dates: Following this, Exagen will hold investor meetings at the Roth Capital Conference in Laguna Niguel, CA, on March 23, 2026, further expanding interaction opportunities with potential investors and boosting market confidence.
- Core Product Overview: Exagen's flagship product, AVISE® CTD, focuses on the early and accurate diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis, assisting clinicians in improving treatment decisions and enhancing clinical outcomes.
- Company Mission and Vision: As a leading provider of autoimmune diagnostics, Exagen is committed to improving care for patients with chronic autoimmune diseases through its innovative testing portfolio, highlighting its leadership in the industry and dedication to patient-centered care.
See More
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen's total revenue for 2025 reached $67 million, marking a 20% year-over-year increase, which demonstrates the company's strong performance and sustained customer demand in its market.
- Test Volume Increase: The AVISE CTD test volume reached between 136,000 and 137,000, an 11% increase over 2024, indicating significant progress in expanding market share and customer base.
- Cash Position: Year-end cash and cash equivalents stood at $32 million, a $10 million increase from 2024, enhancing the company's ability to invest in innovation and expand operations in the future.
- Price Increase: The trailing 12-month average selling price for AVISE CTD rose to $445, up $30 from 2024, reflecting the company's success in enhancing product value and market positioning.
See More
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen anticipates total revenue for 2025 to be between $66 million and $67 million, reflecting a year-over-year growth of 19% to 20%, indicating strong performance and sustained demand in its market.
- Increased Testing Volume: The volume of AVISE CTD tests is projected to reach between 136,000 and 137,000, representing an increase of at least 13,000 tests compared to 2024, showcasing the company's success in product promotion and market acceptance.
- Average Selling Price Increase: The trailing 12-month average selling price for AVISE CTD is expected to rise by $30, reaching between $441 and $445, demonstrating effective strategies in enhancing product value and profitability.
- Strong Cash Position: By the end of 2025, Exagen's cash and cash equivalents are projected to be $32 million, a $10 million increase from 2024, which strengthens the company's financial flexibility for future investments and innovations.
See More
New Factors Influencing Exagen's Story
Exagen's Fair Value and Growth Outlook: Exagen's long-term fair value remains at approximately $15.43 per share, with revenue growth expectations steady at around 15.14%, driven by the expanding adoption of AVISE CTD in autoimmune diagnostics.
Analyst Ratings and Price Targets: B. Riley initiated a Buy rating with a $15 price target, while Canaccord raised its target from $11 to $15, both highlighting the potential of AVISE CTD as a leading diagnostic tool despite sector challenges.
Sector Challenges and Company Confidence: Canaccord warns of pressures in the life science tools sector due to tariffs and funding uncertainties, but Exagen maintains its revenue guidance of $65M to $70M for 2025, aiming for positive adjusted EBITDA by Q4 2025.
Dynamic Investor Narratives: Investors are encouraged to follow Exagen's evolving narrative on Simply Wall St, which connects company performance with future forecasts, helping to inform buy or sell decisions based on the latest updates and market conditions.
See More
Exagen Inc. Reports Record Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Exagen achieved a record $66.6 million in revenue for 2025, nearly a 20% increase over 2024, with testing volume up over 11%, indicating strong performance and sustained customer demand in its market.
- Sales Team Expansion: The sales force expanded from 40 to 45 territories, aiming to drive future revenue growth through broader market coverage and more efficient customer service, which is expected to enhance market share further.
- Product Development Plan: The company plans to launch one new product each year, with a myositis solution targeted for 2027, demonstrating Exagen's strategic commitment to expanding its market opportunities and product portfolio.
- Profitability Outlook: Exagen projects 2026 revenue guidance between $70 million and $73 million, with management confident that breakeven adjusted EBITDA can be achieved at an $80 million revenue run rate, reflecting a strong focus on future growth and investment priorities.
See More
Exagen Reports Q4 Earnings Miss Despite Revenue Growth
- Earnings Performance: Exagen's Q4 GAAP EPS of -$0.20 misses expectations by $0.01, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Growth: The company reported revenue of $16.63 million, reflecting a 21.7% year-over-year increase, surpassing market expectations by $0.06 million, suggesting improved sales performance despite the earnings miss.
- Future Outlook: Exagen anticipates full-year 2026 revenue between $70 million and $73 million, compared to the consensus of $73.84 million, indicating a cautious outlook that may influence shareholder perceptions of its long-term strategy.
- Market Reaction: Despite revenue growth, Exagen's performance lags behind peers like Avino Silver & Gold and Harmony Gold, potentially prompting investors to reassess the risk and return profile of their portfolios.
See More
Exagen Inc. to Participate in Investor Conferences
- Investor Conference Schedule: Exagen Inc. will participate in the virtual KeyBank Capital Markets Healthcare Forum on March 17, 2026, with investor meetings and a fireside chat at 3:00 p.m. ET, aimed at enhancing the company's visibility among investors.
- Key Meeting Dates: Following this, Exagen will hold investor meetings at the Roth Capital Conference in Laguna Niguel, CA, on March 23, 2026, further expanding interaction opportunities with potential investors and boosting market confidence.
- Core Product Overview: Exagen's flagship product, AVISE® CTD, focuses on the early and accurate diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis, assisting clinicians in improving treatment decisions and enhancing clinical outcomes.
- Company Mission and Vision: As a leading provider of autoimmune diagnostics, Exagen is committed to improving care for patients with chronic autoimmune diseases through its innovative testing portfolio, highlighting its leadership in the industry and dedication to patient-centered care.
See More
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen's total revenue for 2025 reached $67 million, marking a 20% year-over-year increase, which demonstrates the company's strong performance and sustained customer demand in its market.
- Test Volume Increase: The AVISE CTD test volume reached between 136,000 and 137,000, an 11% increase over 2024, indicating significant progress in expanding market share and customer base.
- Cash Position: Year-end cash and cash equivalents stood at $32 million, a $10 million increase from 2024, enhancing the company's ability to invest in innovation and expand operations in the future.
- Price Increase: The trailing 12-month average selling price for AVISE CTD rose to $445, up $30 from 2024, reflecting the company's success in enhancing product value and market positioning.
See More
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen anticipates total revenue for 2025 to be between $66 million and $67 million, reflecting a year-over-year growth of 19% to 20%, indicating strong performance and sustained demand in its market.
- Increased Testing Volume: The volume of AVISE CTD tests is projected to reach between 136,000 and 137,000, representing an increase of at least 13,000 tests compared to 2024, showcasing the company's success in product promotion and market acceptance.
- Average Selling Price Increase: The trailing 12-month average selling price for AVISE CTD is expected to rise by $30, reaching between $441 and $445, demonstrating effective strategies in enhancing product value and profitability.
- Strong Cash Position: By the end of 2025, Exagen's cash and cash equivalents are projected to be $32 million, a $10 million increase from 2024, which strengthens the company's financial flexibility for future investments and innovations.
See More
New Factors Influencing Exagen's Story
Exagen's Fair Value and Growth Outlook: Exagen's long-term fair value remains at approximately $15.43 per share, with revenue growth expectations steady at around 15.14%, driven by the expanding adoption of AVISE CTD in autoimmune diagnostics.
Analyst Ratings and Price Targets: B. Riley initiated a Buy rating with a $15 price target, while Canaccord raised its target from $11 to $15, both highlighting the potential of AVISE CTD as a leading diagnostic tool despite sector challenges.
Sector Challenges and Company Confidence: Canaccord warns of pressures in the life science tools sector due to tariffs and funding uncertainties, but Exagen maintains its revenue guidance of $65M to $70M for 2025, aiming for positive adjusted EBITDA by Q4 2025.
Dynamic Investor Narratives: Investors are encouraged to follow Exagen's evolving narrative on Simply Wall St, which connects company performance with future forecasts, helping to inform buy or sell decisions based on the latest updates and market conditions.
See More
